Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

被引：101

作者：

Lokhorst, Henk M. ^{[1
]}

Schmidt-Wolf, Ingo ^{[2
]}

Sonneveld, Pieter ^{[1
]}

van der Holt, Bronno ^{[1
]}

Martin, Hans ^{[2
]}

Barge, Rene ^{[1
]}

Bertsch, Uta ^{[2
]}

Schlenzka, Jana ^{[2
]}

Bos, Gerard M. J. ^{[1
]}

Croockewit, Sandra ^{[1
]}

Zweegman, Sonja ^{[1
]}

Breitkreutz, Iris ^{[2
]}

Joosten, Peter ^{[1
]}

Scheid, Christof ^{[2
]}

van Marwijk-Kooy, Marinus ^{[1
]}

Salwender, Hans-Juergen ^{[2
]}

van Oers, Marinus H. J. ^{[1
]}

Schaafsma, Ron ^{[1
]}

Naumann, Ralph ^{[2
]}

Sinnige, Harm ^{[1
]}

Blau, Igor ^{[2
]}

Delforge, Michel ^{[1
]}

de Weerdt, Okke ^{[1
]}

Wijermans, Pierre ^{[1
]}

Wittebol, Shulamiet ^{[1
]}

Duersen, Ulrich ^{[2
]}

Vellenga, Edo ^{[1
]}

Goldschmidt, Hartmut ^{[2
]}

机构：

[1] Dutch Belgian Hematooncol Cooperat Grp HOVON, Amsterdam, Netherlands

[2] German GMMG, Heidelberg, Germany

来源：

HAEMATOLOGICA | 2007年 / 93卷 / 01期

关键词：

thalidomide; untreated multiple myeloma;

D O I：

10.3324/haematol.11644

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In the prospective phase 3 HOVON-50/GMMG-1-1D3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher afterTAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms.

引用

页码：124 / 127

页数：4

共 20 条

[1] VAD-BASED REGIMENS AS PRIMARY-TREATMENT FOR MULTIPLE-MYELOMA [J].

ALEXANIAN, R ;

BARLOGIE, B ;

TUCKER, S .

AMERICAN JOURNAL OF HEMATOLOGY, 1990, 33 (02) :86-89

[2] Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma [J].

Attal, Michel ;

Harousseau, Jean-Luc ;

Leyvraz, Serge ;

Doyen, Chantal ;

Hulin, Cyrille ;

Benboubker, Lofti ;

Agha, Ibrahim Yakoub ;

Bourhis, Jean-Henri ;

Garderet, Laurent ;

Pegourie, Brigitte ;

Dumontet, Charles ;

Renaud, Marc ;

Voillat, Laurent ;

Berthou, Christian ;

Marit, Gerald ;

Monconduit, Mathieu ;

Caillot, Denis ;

Grobois, Bernard ;

Avet-Loiseau, Herve ;

Moreau, Philippe ;

Facon, Thierry .

BLOOD, 2006, 108 (10) :3289-3294

[3] Thalidomide and hematopoietic-cell transplantation for multiple myeloma [J].

Barlogie, B ;

Tricot, G ;

Anaissie, E ;

Shaughnessy, J ;

Rasmussen, E ;

van Rhee, F ;

Fassas, A ;

Zangari, M ;

Hollmig, K ;

Pineda-Roman, M ;

Lee, C ;

Talamo, G ;

Thertulien, R ;

Kiwan, E ;

Krishna, S ;

Fox, M ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1021-1030

[4] Superior 12-year survival after at least 4-year continuous remiission with tandem transplantations for multiple myeloma [J].

Barlogie, Bart ;

Zangari, Maurizio ;

Bolejack, Vanessa ;

Hollmig, Klaus ;

Anaissie, Elias ;

van Rhee, Frits ;

Pineda-Roman, Mauricio ;

Mohiuddin, Abid ;

Crowley, John ;

Tricot, Guido .

CLINICAL LYMPHOMA & MYELOMA, 2006, 6 (06) :469-474

[5]

Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x

[6] Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma [J].

Cavo, M ;

Zamagni, E ;

Tosi, P ;

Tacchetti, P ;

Cellini, C ;

Cangini, D ;

de Vivo, A ;

Testoni, N ;

Nicci, C ;

Terragna, C ;

Grafone, T ;

Perrone, G ;

Ceccolini, M ;

Tura, S ;

Baccarani, M .

BLOOD, 2005, 106 (01) :35-39

[7] International uniform response criteria for multiple myeloma [J].

Durie, B. G. M. ;

Harousseau, J-L ;

Miguel, J. S. ;

Blade, J. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Dimopoulos, M. ;

Westin, J. ;

Sonneveld, P. ;

Ludwig, H. ;

Gahrton, G. ;

Beksac, M. ;

Crowley, J. ;

Belch, A. ;

Boccadaro, M. ;

Turesson, I. ;

Joshua, D. ;

Vesole, D. ;

Kyle, R. ;

Alexanian, R. ;

Tricot, G. ;

Attal, M. ;

Merlini, G. ;

Powles, R. ;

Richardson, P. ;

Shimizu, K. ;

Tosi, P. ;

Morgan, G. ;

Rajkumar, S. V. .

LEUKEMIA, 2006, 20 (09) :1467-1473

[8] Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients [J].

Goldschmidt, H ;

Sonneveld, P ;

Cremer, FW ;

van der Holt, B ;

Westveer, P ;

Breitkreutz, I ;

Benner, A ;

Glasmacher, A ;

Schmidt-Wolf, IGD ;

Martin, H ;

Hoelzer, D ;

Ho, AD ;

Lokhorst, HM .

ANNALS OF HEMATOLOGY, 2003, 82 (10) :654-659

[9] International staging system for multiple myeloma [J].

Greipp, PR ;

San Miguel, J ;

Durie, BGM ;

Crowley, JJ ;

Barlogie, B ;

Bladé, J ;

Boccadoro, M ;

Child, JA ;

Harousseau, JL ;

Kyle, RA ;

Lahuerta, JJ ;

Ludwig, H ;

Morgan, G ;

Powles, R ;

Shimizu, K ;

Shustik, C ;

Sonneveld, P ;

Tosi, P ;

Turesson, I ;

Westin, J .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3412-3420

[10]

Harousseau JL, 2006, HAEMATOLOGICA, V91, P1498

← 1 2 →